Cell line development is the first step in chemical manufacturing and control (CMC) stage and the basis of process development, which determines quality of final products. Compared with those of monoclonal antibodies (mAbs), Cell line development workload of bispecific antibodies (bsAbs) is larger while development period is longer. How to get a balance between expression level of cell lines, product quality and development time is a challenge that must be faced in developments of bsAbs cell lines. Bioworkshops delivered cell line development projects including mAbs, bsAbs (symmetric + asymmetric), fusion protein and so on with robust process, high expression, scalability and good cell line stability. These projects entered subsequent CMC development stage and clinical research applications that have been successfully approved in the United States, Australia and China. In addition, Bioworkshops can get involved in discovery stage of the partner as well, using professional CMC platform to help screen candidate molecules, shorten the development period, reduce risks in the CMC stage of projects, and push molecules into clinical practice rapidly with robust technology and efficient production.